In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a ...

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P.

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially ...

Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...